$XNCR

GORMAN KEVIN CHARLES sold $93K of XNCR

GORMAN KEVIN CHARLES sold 7,527 shares of Xencor Inc (XNCR) at $12.31 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GORMAN KEVIN CHARLES
Published Jun 17, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XNCR
Neutral
high confidence
Mentioned
$XNCR
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

This disclosure updates the record of insider activity but does not include new operational, financial, or regulatory information that would directly change valuation assumptions.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure and modest dollar value reduce expected fundamental impact.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no explanation for the sale, and no linkage to performance or upcoming events; traders may over-weight the signal versus the plan’s mitigating effect.

Relevance 2/10Novelty 5/10Timing: Filed June 17, 2026 (transaction dated June 15, 2026)

Background

The article is an SEC Form 4 insider transaction for Xencor, reporting a director’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$XNCRNeutralHigh confidence
Context

Xencor director Gorman Kevin Charles sold 7,527 shares in an open-market transaction for about $92.7K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived and sentiment-driven.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, and the disclosed size (~$93K) is modest relative to typical market capitalization effects.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative sentiment signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • Xencor Inc

    Issuer of the securities involved in the Form 4 insider sale; director sold shares under a 10b5-1 plan.

  • Gorman Kevin Charles

    Director who sold 7,527 shares at $12.31/share; holdings after transaction were 11,378 shares.

Related articles

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xncr-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indica

$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

$XNCRMedAI 8/10

Xencor, Inc.: Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter

Xencor (NASDAQ:XNCR) said it reached a settlement with Alexion to resolve a U.S. Ultomiris (ravulizumab-cwvz) royalty dispute. Under the agreement, Xencor will receive $105 million in two $52.5 million payments, expected in Aug. 2026 and one year later. Alexion will owe no further U.S. royalties, while ex-U.S. royalties continue. Xencor expects cash through 2028.

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. xncr-20260729 FALSE 0001326732 0001326732 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 8-K ___________________________________________________ CURRENT REPORT Pursuant to Sect